Drug combination shows significant survival advantage in metastatic RCC

Article

The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11).

Recent Videos
Elisabeth M. Sebesta, MD, answers a question during a Zoom video interview
Kyrollis Attalla, MD, an expert on prostate cancer
Kyrollis Attalla, MD, an expert on prostate cancer
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Jacqueline Zillioux, MD, answers a question during a Zoom video interview
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.